Answers are grounded in this paper and cite their sources.
Preclinical models show increased diagnostic efficacy with a new gadolinium chelate, suggesting clinical translation potential.
Digadoglucitol shows high diagnostic efficacy in preclinical models of neurological and oncological diseases. It delivers comparable effectiveness at half the dose and superior contrast enhancement at the full standard dose compared with established GBCAs. These preclinical findings suggest that digadoglucitol is a promising contrast agent to be considered for clinical translation, potentially allowing for reduced dosage while maintaining or improving diagnostic accuracy.
No takes yet. Share an insight, caveat, or question.
Cava et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: